Worth reading
42Recurring
Scored from 5 of 6 sectionsDirection
Improvement
Direction inferred from the company’s description.Scale
21.3
Revenue change year on year (%)Wording
Conditional
How definitive the wording is.Results for this period
First quarter1 July 2026–30 September 2026ConsolidatedJapanese GAAPNet Sales43,729Millions of yenYear on year +21.3%Progress 27.0%
Operating profit17,569Millions of yenYear on year +34.8%Progress 33.7%
Ordinary income17,909Millions of yenYear on year +39.0%Progress 34.0%
Net income attributable to owners of the parent12,706Millions of yenYear on year +38.0%Progress 33.6%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share¥47.89
Financial position at period-end
Total assets207,106Millions of yen
of which net assets 171,455 Millions of yenEquity ratio 82.3%vs. prior year-end +2.9pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Segment revenueMedical Business 38,438 Millions of yen (YoY +21.4%), Device Business 5,291 Millions of yen (YoY +20.6%)
Segment profitMedical Business 18,553 Millions of yen (YoY +48.4%), Device Business 1,372 Millions of yen (YoY -44.4%)
Regional salesRegion Japan / Current fiscal year 5,659 Millions of yen / Same period of the previous year 4,963 Millions of yen, Region North America / Current fiscal year 10,181 Millions of yen / Same period of the previous year 7,437 Millions of yen, Region Europe / Current fiscal year 8,395 Millions of yen / Same period of the previous year 7,765 Millions of yen, Region China / Current fiscal year 12,094 Millions of yen / Same period of the previous year 9,800 Millions of yen, Region Other / Current fiscal year 7,397 Millions of yen / Same period of the previous year 6,091 Millions of yen
Outlook and shareholder returns
Full-year earnings forecast
Net Sales161,794 Millions of yen (YoY +11.3%)
Operating profit52,127 Millions of yen (YoY +15.3%)
Ordinary income52,600 Millions of yen (YoY +16.4%)
Net income37,832 Millions of yen (YoY +17.9%)
Revision to Earnings ForecastNo revision
Annual Dividend Forecast48.24 Yen → 49.91 Yen
Factors Behind Changes in Business Performance
Strong performance in the Medical and Devices businesses, the positive impact of foreign exchange movements, higher net sales, improved productivity, and lower cost of sales due to refunds of customs duties paid in prior years, among other factors. Operating income increased as the rise in gross profit exceeded the increase in selling, general and administrative expenses.
Disclosure regarding the going concern assumption
None
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNew 0 companies / Excluded 0 companies / Company name Not applicable
Material subsequent eventsNone
Breakdown of extraordinary income (loss)Current fiscal year None applicable
Depreciation and amortization2,134 Millions of yen
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingWhether applicable Yes / Subject person Institutional investors and analysts
Issued Shares at Period-End265,332,300 shares
Treasury Shares at Period-End7,977 shares
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 July 2026–30 September 2026 |
| Net Sales | 43,729 Millions of yen (YoY +21.3%) |
| Operating profit | 17,569 Millions of yen (YoY +34.8%) |
| Ordinary income | 17,909 Millions of yen (YoY +39.0%) |
| Profit attributable to owners of the parent | 12,706 Millions of yen (YoY +38.0%) |
| Net income per share | ¥47.89 |
| Equity ratio | End of the current fiscal period 82.3 / End of previous period 79.4 |
| Total assets | 207,106 Millions of yen |
| Net assets | 171,455 Millions of yen |
| Full-year earnings forecast | Net Sales 161,794 Millions of yen (YoY +11.3%) / Operating profit 52,127 Millions of yen (YoY +15.3%) / Ordinary income 52,600 Millions of yen (YoY +16.4%) / Net income 37,832 Millions of yen (YoY +17.9%) |
| Revision to Earnings Forecast | No revision |
| Annual Dividend Forecast | 48.24 Yen → 49.91 Yen |
| Segment revenue | Medical Business 38,438 Millions of yen (YoY +21.4%), Device Business 5,291 Millions of yen (YoY +20.6%) |
| Segment profit | Medical Business 18,553 Millions of yen (YoY +48.4%), Device Business 1,372 Millions of yen (YoY -44.4%) |
| Regional sales | Region Japan / Current fiscal year 5,659 Millions of yen / Same period of the previous year 4,963 Millions of yen, Region North America / Current fiscal year 10,181 Millions of yen / Same period of the previous year 7,437 Millions of yen, Region Europe / Current fiscal year 8,395 Millions of yen / Same period of the previous year 7,765 Millions of yen, Region China / Current fiscal year 12,094 Millions of yen / Same period of the previous year 9,800 Millions of yen, Region Other / Current fiscal year 7,397 Millions of yen / Same period of the previous year 6,091 Millions of yen |
| Depreciation and amortization | 2,134 Millions of yen |
| Breakdown of extraordinary income (loss) | Current fiscal year None applicable |
| Disclosure regarding the going concern assumption | None |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 companies / Excluded 0 companies / Company name Not applicable |
| Material subsequent events | None |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable Yes / Subject person Institutional investors and analysts |
| Issued Shares at Period-End | 265,332,300 shares |
| Treasury Shares at Period-End | 7,977 shares |
| Factors Behind Changes in Business Performance | Strong performance in the Medical and Devices businesses, the positive impact of foreign exchange movements, higher net sales, improved productivity, and lower cost of sales due to refunds of customs duties paid in prior years, among other factors. Operating income increased as the rise in gross profit exceeded the increase in selling, general and administrative expenses. |
Items this document does not state (9)
Operating MarginCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodPayout ratioShareholder Return PolicyOrders received and order backlogImpairment loss
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Both the Medical and Devices businesses performed well, and foreign exchange movements had a positive impact. On the earnings side, the increase in gross profit exceeded the increase in selling, general and administrative expenses, while foreign exchange losses decreased and foreign exchange gains increased.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.